Compare UDMY & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UDMY | DBVT |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 2014 |
| Metric | UDMY | DBVT |
|---|---|---|
| Price | $4.97 | $21.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $9.00 | ★ $31.75 |
| AVG Volume (30 Days) | ★ 2.2M | 253.8K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.36 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $789,844,000.00 | $4,151,000.00 |
| Revenue This Year | $4.44 | $1,768.71 |
| Revenue Next Year | $6.02 | $1,028.88 |
| P/E Ratio | $175.00 | ★ N/A |
| Revenue Growth | ★ 0.42 | N/A |
| 52 Week Low | $4.35 | $3.82 |
| 52 Week High | $9.74 | $26.19 |
| Indicator | UDMY | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 48.32 |
| Support Level | $5.02 | $20.11 |
| Resistance Level | $5.06 | $25.52 |
| Average True Range (ATR) | 0.26 | 1.32 |
| MACD | 0.07 | -0.17 |
| Stochastic Oscillator | 66.83 | 22.49 |
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.